Periostin promotes liver steatosis and hypertriglyceridemia through downregulation of PPARα
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Hepatosteatosis is characterized by an aberrant accumulation of triglycerides in the liver; however, the factors that drive obesity-induced fatty liver remain largely unknown. Here, we demonstrated that the secreted cell adhesion protein periostin is markedly upregulated in livers of obese rodents and humans. Notably, overexpression of periostin in the livers of WT mice promoted hepatic steatosis and hypertriglyceridemia. Conversely, both genetic ablation of periostin and administration of a periostin-neutralizing antibody dramatically improved hepatosteatosis and hypertriglyceridemia in obese mice. Overexpression of periostin resulted in reduced expression of peroxisome proliferator-activated receptor α (PPARα), a master regulator of fatty acid oxidation, and activation of the JNK signaling pathway. In mouse primary hepatocytes, inhibition of α6β4 integrin prevented activation of JNK and suppression of PPARα in response to periostin. Periostin-dependent activation of JNK resulted in activation of c-Jun, which prevented RORα binding and transactional activation at the Ppara promoter. Together, these results identify a periostin-dependent pathway that mediates obesity-induced hepatosteatosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
A central role for JNK in obesity and insulin resistance
Hirosumi, J., Tuncman, G., Chang, L., Görgün, C. Z., Uysal, K. T., Maeda, K., Karin, M., & Hotamisligil, G. S. (2002) · Nature · doi:10.1038/nature01137 · Cited by 3,359 · cited 1×
“In addition, studies using genetically engineered mice have shown that hyper-activation of the JNK pathway contributes to the development of metabolic diseases, including hepatic steatosis, obesity, and insulin resistance (36–38).”
SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase
Bennett, B. L., Sasaki, D. T., Murray, B. W., O'Leary, E. C., Sakata, S. T., Xu, W., Leisten, J. C., Motiwala, A., Pierce, S., Satoh, Y., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251194298 · Cited by 2,558 · cited 1×
“First, mice overexpressing periostin by adenoviral Postn were treated with SP600125, a classic JNK kinase inhibitor (22).”
Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications
Fabbrini, E., Sullivan, S., & Klein, S. (2010) · Hepatology · doi:10.1002/hep.23280 · Cited by 2,100 · cited 2×
“Hepatosteatosis occurs when TG homeostasis is disrupted, due to increased de novo lipogenesis and fatty acid uptake and reduced fatty acid oxidation and VLDL export (4, 5).”
Human Fatty Liver Disease: Old Questions and New Insights
Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2011) · Science · doi:10.1126/science.1204265 · Cited by 2,089
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
Anstee, Q. M., Targher, G., & Day, C. P. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.41 · Cited by 1,747
Peroxisome proliferator–activated receptor α mediates the adaptive response to fasting
Kersten, S., Seydoux, J., Peters, J. M., Gonzalez, F. J., Desvergne, B., & Wahli, W. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6223 · Cited by 1,649
Badman, M. K., Pissios, P., Kennedy, A. R., Koukos, G., Flier, J. S., & Maratos-Flier, E. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.002 · Cited by 1,495
Interactions between cancer stem cells and their niche govern metastatic colonization
Malanchi, I., Santamaria-Martínez, A., Susanto, E., Peng, H., Lehr, H.-A., Delaloye, J.-F., & Huelsken, J. (2012) · Nature · doi:10.1038/nature10694 · Cited by 1,339
Rational design and characterization of a Rac GTPase-specific small molecule inhibitor
Gao, Y., Dickerson, J. B., Guo, F., Zheng, J., & Zheng, Y. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307512101 · Cited by 1,091 · cited 1×
“To further determine whether Rac1 is required for JNK activation by periostin, we pretreated HepG2 cells with the Rac1 antagonist NSC23766 (27), which largely abolished the JNK phosphorylation induced by periostin (Supplemental Figure 8B).”
Cited by
PPARs as Metabolic Regulators in the Liver: Lessons from Liver-Specific PPAR-Null Mice
Wang, Y., Nakajima, T., Gonzalez, F. J., & Tanaka, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062061 · Cited by 540
Immunomodulatory Role of the Extracellular Matrix Within the Liver Disease Microenvironment
McQuitty, C. E., Williams, R., Chokshi, S., & Urbani, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.574276 · Cited by 146
Orosomucoid 2 maintains hepatic lipid homeostasis through suppression of de novo lipogenesis
Zhou, B., Luo, Y., Ji, N., Hu, C., & Lu, Y. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00627-4 · Cited by 75
Wang, H., Zhu, Y.-Y., Wang, L., Teng, T., Zhou, M., Wang, S.-G., Tian, Y.-Z., Du, L., Yin, X.-X., & Sun, Y. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.10.022 · Cited by 67
Xie, W., Gan, J., Zhou, X., Tian, H., Pan, X., Liu, W., Li, X., Du, J., Xu, A., Zheng, M., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.04.020 · Cited by 55
Self-citation
Metadata
- Authors
- Lu, Y., Liu, X., Jiao, Y., Xiong, X., Wang, E., Wang, X., Zhang, Z., Zhang, H., Pan, L., Guan, Y., Cai, D., Ning, G., & Li, X.
- Venue
- Journal of Clinical Investigation
- Published
- 2014-07-08
- Volume
- 124
- Issue
- 8
- Pages
- 3501-3513
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2065257841
- Cited by
- 131
- References
- 21
- FWCI
- 7.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Periostin promotes liver steatosis and hypertriglyceridemia through downregulation of PPARα. https://app.cochat.ai/papers/10.1172/jci74438
- The paper
- Lu, Y., Liu, X., Jiao, Y., Xiong, X., Wang, E., Wang, X., Zhang, Z., Zhang, H., Pan, L., Guan, Y., Cai, D., Ning, G., & Li, X. (2014). Periostin promotes liver steatosis and hypertriglyceridemia through downregulation of PPARα. Journal of Clinical Investigation. https://doi.org/10.1172/jci74438
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.